Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Note: Please note that if the hit list contains both a subproject and its parent grant, the subproject funding is already included in the parent project funding amount.
* Funding data available only for NIH, CDC, FDA, AHRQ, and ACF.
Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection
AIDS: December 1, 2021 - Volume 35 - Issue 15 - p 2423-2432
Methods
Cell lines, reagents and virus
SupT1.R5 cells (CD4+CCR5+CR2+) were provided by J.A. Hoxie (University of Pennsylvania), A3R5.7 cells by D.C. Montefiori (Duke University), SHIV-1157ip [23] gp120 and gp160 by S.L. Hu (University of Washington), mAb Fm-6-IgG1 by W.A. Marasco (Dana-Farber Cancer Institute), and HIV-1MN gp41, consensus-clade C peptides, and CN54 gp140 [24] by the NIH AIDS Reagent Program. We generated reporter virus NL-LucR.1157ipd3N4 by cloning SHIV-1157ipd3N4 [25]env into plasmid pNL-LucR.T2A (provided by C. Ochsenbauer, University of Alabama). SHIV-1157ipd3N4 stock [grown in rhesus macaque peripheral blood mononuclear cells (PBMC)] contained 713 ng/ml of p27 and 7 × 106 50% tissue culture infectious doses (TCID50)/ml (measured in TZM-bl cells).
Intrarectal SHIV-1157ipd3N4 challenge
To test the hypothesis that early-stage anti-HIV Env IgG enhances in-vivo viral acquisition, we performed an end-point virus titration in macaques, using an upfront heterologous, R5 tier 2 clade C SHIV. To avoid confounding influences of different viral quasi-species, we selected an infectious molecular clone, SHIV-1157ipd3N4 [25]. We enrolled two groups of eight macaques. First, we determined minimal infectious and 50% animal infectious doses (AID50) in naive animals, which were sequentially exposed intrarectally to increasingly diluted SHIV stock (Fig. 4). After a given animal's viremia was >104 copies/ml, the next macaque was inoculated with a ten-fold higher virus-stock dilution, until a 1 : 10,000 dilution failed to infect. Subsequent animals were then exposed to intermediate dilutions; animals that remained aviremic on day 28 after initial challenge were re-exposed to a high virus inoculum (1 : 2 dilution of the stock); all such animals became viremic (Fig. 5a).
https://journals.lww.com/aidsonline/Fulltext/2021/12010/Mucosal_AIDS_virus_transmission_is_enhanced_by.2.aspx
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fcdn-links.lww.com%2Fpermalink%2Fqad%2Fc%2Fqad_2021_08_10_ruprecht_aids-d-21-00364_sdc1.docx&wdOrigin=BROWSELINK
Imagine in last link in last post
isn't what I'm seeing right now
:}
U19AI142636 Publications
https://reporter.nih.gov/search/K-ztMzgyCk25GZC9F4Nb-A/publications?sort_field=pub_year&sort_order=desc
AIDS (London, England) 2021 12 01
AIDS 2021 Dec
Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection
https://pubmed.ncbi.nlm.nih.gov/34402452/
The finish line ?
https://reporter.nih.gov/search/K-ztMzgyCk25GZC9F4Nb-A/projects/charts
Ronald Kempers has to gist us, right
but no so muck Ronald Kempers
Someone important
:}
universal sterilizing HIV vaccine
https://www.nejm.org/doi/full/10.1056/NEJMcibr1304437
Margaret Ackerman on a few w/ Chris Gast
Preprint
&
IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
https://orcid.org/0000-0002-4253-3476
Massachusetts Institute of Technology, Cambridge, MA & Harvard
Ackerman Lab
Dartmouth
https://www.ackermanlab.org/ackerman.html
Specifically, she studied the levels of Immunoglobulin A (IgA) antibodies in their mucus.[11] Her research identified that people who suffered from more mild cases of COVID-19 displayed increased levels of IgA. She also showed that there was an anti-correlation between levels of IgA and IgG, i.e., people with high IgA levels had low IgG levels.[11]
https://en.wikipedia.org/wiki/Margaret_Ackerman
Ref 11
https://engineering.dartmouth.edu/news/milder-cases-of-covid-19-linked-to-iga-antibodies
Georgia D. Tomaras & David Montefiori finally show back up
My, isn't Ruth something else
Gast Statistical Consulting, LLC
https://www.buzzfile.com/business/Gast-Statistical-Consulting,-LLC-206-569-5565
Employees Here :3
https://clustrmaps.com/person/Gast-aqlcct
Chris Gast Director of Statistics - PATH CVIA
Bill & Melinda Gates Foundation.
Biostatistics Consultant, Seattle, Washington.
https://www.linkedin.com/in/chris-gast-301602b0
PATH
Seattle, Washington • 2,500 Employees
International Affairs
https://www.apollo.io/people/Chris/Gast/57dfefa4a6da980ad27cb241
https://rocketreach.co/chris-gast-email_18820546
https://rocketreach.co/c3-research-associates-profile_b5e25031f42e6254
https://www.c3-research.com/
My they changed the link in that last post really fast lol
Dr. Erwann Loret (Marseille University, France)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155119925
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159283863
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157267887
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163114060
https://retrovirus.conferenceseries.com/abstract/2015/hiv-extracellular-tat-myth-or-reality
but no results w/ google for that same search on these
LOL
Ruth M. Ruprecht Correspondence:
Dr. Ruth Ruprecht<br/>email:ruth.ruprecht@louisiana.edu<br/>University of Louisiana at Lafayette, New Iberia Research Center
11:41 AM, 10 January 2022
Ruth M. Ruprecht
https://loop.frontiersin.org/people/997152/overview
1 Editorial Contributions
1 Reviewed Publications
https://loop.frontiersin.org/people/997152/editorial
The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity
Morgane Bomsel
Published Feb 2021
1,958 views
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167994043
Pg 1 Mymetics / Catalent patent
Other Publications
2011
Bomsel
Leading to the 2013 published vaginal study in women in Ghent Belgium
100 %
Bill Gates angered some experts over the weekend
So he is changing direction & shifting gears
https://finance.yahoo.com/news/we-need-to-think-about-the-covid-19-vaccines-well-need-in-3-to-5-years-public-health-expert-155855572.html
Definitely encouraged by that white paper
Looks like we are getting somewhere
Later
This article has more views than 11% of all Frontiers articles.
View article impart
http://loop-impact.frontiersin.org/impact/article/788619#totalviews/views
From
602 views in three days yet 47 views in Jan
on one tweet from Frontiers
I haven't seen that from Mymetics brother
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
Interesting Demographics
http://loop-impact.frontiersin.org/impact/article/788619#demographics
w/ no citations yet
Why do I see t.co as a referral source in Google Analytics?
https://www.thesocialmediahat.com/blog/why-do-i-see-t-co-as-a-referral-source-in-google-analytics/
;}
Groups
Wyss Community Networking Group
Wyss Community Networking Group Graphic
Wyss Community Networking Group
-
Stony Brook University Alumni Association
Stony Brook University Alumni Association Graphic
Stony Brook University Alumni Association
-
Vaccine Professionals Group
Vaccine Professionals Group Graphic
Vaccine Professionals Group
-
" HORIZON EUROPE " Framework Programme for Research and Innovation
" HORIZON EUROPE " Framework Programme for Research and Innovation Graphic
" HORIZON EUROPE " Framework Programme for Research and Innovation
-
Robert oversees the entire biosafety program at the Wyss Institute. His work includes making full biosafety risk assessments of all Institute projects involving human and animal biologicals, and recombinant and synthetic genetic material; he also ensures the experiments will be done in compliance with NIH guidelines, OSHA Bloodborne Pathogen Standard, and all state and local regulations. Robert serves as the liaison between the Wyss Institute and the Committee on Microbiological Safety (COMS), Harvard University’s Institutional Biosafety Committee that oversees research at the Wyss Institute; Robert also provides risk evaluation and guidance for COMS protocol submission by Wyss Institute Investigators. As biosafety officer, Robert also provides project-appropriate group and individual biosafety training to Wyss researchers. Before coming to the Wyss in 2016, Robert was a biosafety officer at Dana-Farber Cancer Institute for three years. Prior to entering the field of biosafety, Robert was an Assistant Professor of Medicine at Harvard Medical School and AIDS vaccine researcher at Dana-Farber, working both as a senior investigator and project leader, as well as performing experiments. Rob received his B.S. from Stony Brook University and his Ph.D. from the State University of New York, Downstate Medical Center.
https://wyss.harvard.edu/team/biosafety-and-lab-safety/robert-rasmussen/
Robert Anthony Rasmussen
Senior Director of Research Operations
Harvard's Wyss Institute for Biologically Inspired Engineering
Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus
https://www.researchgate.net/publication/266085524_Multimodality_vaccination_against_clade_C_SHIV_Partial_protection_against_mucosal_challenges_with_a_heterologous_tier_2_virus
https://pubmed.ncbi.nlm.nih.gov/33677480/
Vaccine protection by virosome-induced IgG and IgA parallels the cooperation between systemically administered IgG1 and mucosally applied dimeric IgA2 monoclonal antibodies that as single-agents provided no/low protection – but when combined, prevented mucosal SHIV transmission in all passively immunized RMs.
Interesting search results
Thanks to the poster
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167989839
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
Malaria vaccine - Mymetics
27 Sep 2021 Biomarkers information updated
https://adisinsight.springer.com/drugs/800019935
Orphan riddle, right
EDITED BY
Andreas Frey
Research Center Borstel (LG), Germany
REVIEWED BY
Mariangela Cavarelli
Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), France
Mauricio Martins
The Scripps Research Institute, United States
& SGR knowns more about it than us
}
May not be my place, but I'll answer yes
RK learned a lot, shop it around, diplomatically & tip toe around it, then Sanofi may understand that, nothing public in Hiv research that isn't dirty
:}
March 31st last year
Did you find it interesting
that you can build fud in a whitepaper again yet cross the finish line ?
That rectal challenge has to be done as well b/c funding coming up in May for Nih Hiv
Trying not to chase shinny objects here but Mario & Nih Gmp meeting, what Dec 2020 for no reason
:}
No acquisition: a new ambition for HIV vaccine development?
& the smart money can't figure it out
Gee
:}
https://pubmed.ncbi.nlm.nih.gov/22081778/
It should be noted that the challenge route was intravaginal – quite different from all other preclinical AIDS vaccine development studies that mostly used the intrarectal challenge route.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167989839
Thanks to the poster
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167992784
What would that be worth to big pharma since no one wants to talk about pig pharma's failures in this
?
Samir Lakhashe
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166534350
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164516682
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152575550
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157817637
So they learned some things
That it works in Chinese-origin rhesus macaques & Indian rhesus macaques, each a lil different
& that it works differently in the young & old kinda like Mr Kempers mentioned in his first Biople piece w/ covid
Yet they have 100% protection against multiple intra-vaginal challenges here
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167924874
Is it enough, the smart money will know
VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA
grant OPP1146996 to M.S.S. A.F. is recipient of a Canada Research Chair
https://einstein.pure.elsevier.com/en/publications/vsv-displayed-hiv-1-envelope-identifies-broadly-neutralizing-anti
Montefi ori: Antibody Vaccine Immune Monitoring Consortium
OPPID. 1146996. Grant Award. Up to $33.8
https://www.cavd.org/Grantee%20Profiles%20%202018/Montefiori%20OPP1146996%20Antibody%20Vaccine%20Immune%20Monitoring%20Consortium.pdf
Duke-Led Team Develops More Accurate Tool to Track New HIV Infections
OPP1146996
https://www.newswise.com/articles/duke-led-team-develops-more-accurate-tool-to-track-new-hiv-infections
Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide
2 and destroys a neutralizing epitope
Cal Tech
Melinda Gates Foundation grant (#OPP1146996 to M.S.S.). M.C.N. is an HHMI Investigator.
https://www.biorxiv.org/content/10.1101/2021.03.17.435265v1.full.pdf
& more
& the others
Grant P51 OD011133
grant P30 AI064518
Bill & Melinda Gates Foundation
Committed Grants
https://www.angst-frei.ch/network/bmgf
From that
Grant OPP1111654
DATE
OCTOBER 2014
REGION SERVED
GLOBAL
DURATION (MONTHS)
30
https://www.gatesfoundation.org/about/committed-grants/2014/10/opp1111654
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
and the Bill and Melinda Gates Foundation (CAVD) grant #OPP1146996 (to MSS). Additional support included the NIH
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577740/
Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope
and a Bill and Melinda Gates Foundation grant (#OPP1146996 to M.S.S.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545924/
Distinct clonal evolution of B-cells in HIV
controllers with neutralizing antibody
breadth
grant
#OPP1066973 and #OPP1146996.
https://elifesciences.org/articles/62648.pdf
Broadly Neutralizing Antibodies for HIV-1 Prevention
rant #OPP1146996
https://www.frontiersin.org/articles/10.3389/fimmu.2021.712122/full
The Bertarelli Program in Translational Neuroscience and Neuroengineering was founded in 2010 as a joint research and education initiative between the Ecole polytechnique fédérale de Lausanne (EPFL) and Harvard Medical School (HMS).
https://www.fondation-bertarelli.org/life-sciences/harvard/
Dona Bertarelli
https://en.wikipedia.org/wiki/Dona_Bertarelli
https://www.bertarelli.com/family/dona-bertarelli/
Only 30 pairs of Amsterdam Island albatross remain in the world—and France has protected their home.
Happy #WorldWhaleDay!
https://twitter.com/DonaBertarelli?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
A Swiss philanthropist, investor, sportswoman
https://donabertarelli.com/dona-bertarelli/
& Amy Wyss is still under water on her Anergis investment
LOL
Raul Tonda
https://es.linkedin.com/in/raul-tonda-79b70243?challengeId=AQH1CwD5hMIeHAAAAX8dGF4mJ-yHs2QAdea0BRZQWA2K8ViULFKeBfkwcseycNQMBivMVZOebdvcjLYw6apcjQlN7C6wPKAdHQ&submissionId=dfe221f8-b4d9-d516-543c-b2ca56ef8627
https://orcid.org/0000-0001-7893-2404
https://www.researchgate.net/profile/Raul-Tonda
Certificate of Completion: SQL Fundamentals
@ least we can feel sorry for him
but we still need a Biotech Ceo
LOL
Let's get the Who involved w/ Hiv day in Tehran, oops just did
https://pubmed.ncbi.nlm.nih.gov/22809863/
It's a bioinspiration
Reinhard Glueck Maria Bottazzi Gaurav Gupta & Steven Reed
Laboratory of Malaria and Vector Research
&
the Spaniards
Does Toon Stegmann have a head hunter after him Mr Kempers
?
Big Bonanza a year early
b/c the books needed cleaned maybe ?
We are here to find out so they take us w/ them or screw us
Later
Merck Research Laboratories president Roger Perlmutter said: “Scientists at Immune Design have established a unique portfolio of approaches to cancer immunisation and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development.
The drug candidate has been evaluated in various clinical trials, including in combination with Merck’s anti-PD-1 checkpoint inhibitor Keytruda.
“This acquisition builds upon Merck’s industry-leading programmes that harness the power of the immune system to prevent and treat disease.” The company’s lead product candidate G100 is a potent intratumoral TLR4 agonist designed to use a range of endogenous antigens to generate a systemic anti-tumour immune response. It is indicated for Non-Hodgkin’s Lymphoma.
https://www.pharmaceutical-technology.com/news/merck-acquires-immune-design/
Vaccine Composition Containing Synthetic Adjuvant
Steven G Reed
Pilot Trial of Intratumoral G100
Gluck, Immunopotentiating Reconstituted Influenza Virosomes (IRIVs) and other adjuvants for improved presentation of small antigens, Vaccine, 10(13):915-9 (1992).
https://portal.unifiedpatents.com/patents/patent/US-9987355-B2
T-win something or another, right Ronald ?
Immune Design Corp Cancer antigens
The individual ID-VP02 genome
Delivery can be achieved by contacting the dendritic cells with a virosome ex vivo, whereupon the infected dendritic cells are provided to the patient. At other times, delivery may be achieved by delivering the virus to the subject in order to infect dendritic cells in vivo. The dendritic cells then stimulate antigen-specific T cells or B cells in the patient to induce cellular and humoral immune responses to the expressed antigen. In this manner, a patient suffering from a disease or disorder is treated by generating immune cells with the desired specificity.
https://patents.google.com/patent/CN104583231B/en
Merck owns that now
& Intl comes back, sees
it not that long to wait for
Fast Track Designation
LOL
Feb 21, 2013 Preclinical studies in non-human primates already generated extremely promising data demonstrating 100% protection against multiple intra-vaginal challenges with a live virus."
Providing Mymetics obtains additional sources of financing for this project, the company plans to test its prophylactic HIV-1 vaccine candidate in a combined Phase I and II trial to investigate an additional HIV-1 antigen and a further optimized vaccine formulation.
https://finance.yahoo.com/news/data-published-plos-one-show-073000012.html?fr=sycsrp_catchall
Pending this data, a combined Phase I/II on women and men might start by 2022.
https://www.otcmarkets.com/filing/html?id=14842380&guid=wYWwk621Ej5cdth
Pending this data, a combined Phase I/II on women and men might start by 2021
https://www.otcmarkets.com/filing/html?id=14041707&guid=wYWwk621Ej5cdth
We are eagerly awaiting the results of our NIH-funded project
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167129437
They are clearly working on Hiv
& Intl says bye
LOL
I like the dates on this
M&A Details
Immune Design was acquired by Merck for $300M on Feb 21, 2019.
Transaction Name
Immune Design acquired by Merck Logo
Immune Design acquired by Merck
Acquired by
Merck Logo
Merck
Announced Date Feb 21, 2019
Price $300M
https://webcache.googleusercontent.com/search?q=cache:crDo8ruNmdIJ:https://xconomy.com/seattle/2014/07/24/immune-design-receives-60000000-new-funding-round/+&cd=3&hl=en&ct=clnk&gl=us
Cancer research company Immune Design raises $60M in IPO
https://www.geekwire.com/2014/immune-design-raises-60m-ipo/
Now, about dem taxes
https://www.crunchbase.com/person/david-baltimore
Where did Tamara S go to school ?
LOL
Founders Steven Reed
https://www.crunchbase.com/organization/immune-design
From pg 16 placebo vaccine vp02 Catalent patent
Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors
Authors
Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA
Vector production and quantitation
ZVex/OVA vectors were designed and produced based on the VP02 platform previously described44. Briefly, vectors were produced via the transient transfection of 293T cells with 5 plasmids: the transfer vector that encodes the VP02 genome and ovalbumin, a modified gagpol transcript (RI-gagpol), accessory protein Rev from HIV-1, accessory protein Vpx from SIVmac, and the E1001 envelop glycoprotein variant of Sindbis virus.
https://www.nature.com/articles/s41541-020-0201-x
ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities
https://www.researchgate.net/publication/343768011_ZVex_a_dendritic-cell-tropic_lentivector_primes_protective_antitumor_T_cell_responses_that_are_significantly_boosted_using_heterologous_vaccine_modalities
ZVex
HIV-1 Conserved Mosaics Delivered by Regimens
with Integration-Deficient DC-Targeting Lentiviral
Vector Induce Robust T Cell
https://www.cell.com/molecular-therapy-family/molecular-therapy/pdfExtended/S1525-0016(16)45421-3
VP02, of the ZVex platform
https://www.pubfacts.com/detail/26942209/Design-of-a-titering-assay-for-lentiviral-vectors-utilizing-direct-extraction-of-DNA-from-transduced
Immune Design , Seattle, Washington, USA.
& I'm sure there is more
CAMERA BASED DOCKING OF VEHICLES USING ARTIFICIAL INTELLIGENCE
Everyone knows who Siemens is
https://patents.justia.com/inventor/christian-herzog
https://en.wikipedia.org/wiki/ZF_Friedrichshafen
https://www.zf.com/mobile/en/homepage/homepage.html
A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador
https://scielosp.org/article/rpsp/2010.v27n2/117-124/
Berna Biotech / the Swiss Serum and Vaccine Institute
w/ R G
Right Mario
https://ch.linkedin.com/in/christianherzog47
Epaxal® : Clinical Experience with the Only Aluminium-free Hepatitis A Vaccine
https://www.piv.or.kr/DOIx.php?id=10.14776/kjpid.2006.13.1.31
Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine
https://pubmed.ncbi.nlm.nih.gov/19450630/
& Merck is paying out for using it
..................
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!